Ribon Therapeutics Overview
- Founded
- 2015

- Status
- Private
- Employees
- 47

- Latest Deal Type
- Series B
- Latest Deal Amount
- $65M

- Investors
- 10
Ribon Therapeutics General Information
Description
Developer of a biotech platform intended to block cancer cell's fundamental ability to survive under stress. The company's offerings include discovery and development of first-in-class small molecule inhibitors or each enzyme in the target family, enabling doctors to help treat patients suffering from cancer.
Contact Information
- 35 Cambridgepark Drive
- Cambridge, MA 02140
- United States
Ribon Therapeutics Timeline
Ribon Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC (Series B) | 04-Jan-2019 | $65M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
1. Early Stage VC (Series A) | 10-Oct-2017 | 000.00 | 000.00 | 000.00 | Completed | Startup |
Ribon Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Ribon Therapeutics Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialRibon Therapeutics Competitors (33)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Apexian | Venture Capital-Backed | Indianapolis, IN | 0 | 000.00 | 00000000000 | 000.00 |
0000000 0000000000 | Venture Capital-Backed | New York, NY | 00 | 000.00 | 0000000000 | 000.00 |
000000000 | Venture Capital-Backed | Gaithersburg, MD | 00 | 000.00 | 00000000000 | 000.00 |
00000000 000000000 | Venture Capital-Backed | Uppsala, Sweden | 00 | 0000000000 | ||
000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Ribon Therapeutics Executive Team (10)
Ribon Therapeutics Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Anja König Ph.D | Novartis Venture Fund | Board Member | 000 0000 |
Cameron Wheeler Ph.D | Deerfield Management | Board Member | 000 0000 |
Emma Reeve | Self | Board Member | 000 0000 |
James Audia Ph.D | Self | Board Member | 000 0000 |
Jodie Morrison | Self | Chairman | 000 0000 |
Ribon Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialRibon Therapeutics Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Celgene | Corporation | Minority | 000 0000 | 000000 0 | |
Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 |